Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients

被引:25
|
作者
Karabon, L. [1 ,2 ]
Partyka, A. [1 ]
Ciszak, L. [1 ]
Pawlak-Adamska, E. [1 ]
Tomkiewicz, A. [1 ]
Bojarska-Junak, A. [3 ]
Rolinski, J. [3 ]
Wolowiec, D. [4 ]
Wrobel, T. [4 ]
Frydecka, I. [1 ]
Kosmaczewska, A. [1 ]
机构
[1] Polish Acad Sci, Hirszfeld Inst Immunol & Expt Therapy, Dept Expt Therapy, Wroclaw, Poland
[2] Wroclaw Med Univ, Dept & Clin Urol & Oncol Urol, Wroclaw, Poland
[3] Med Univ Lublin, Dept Clin Immunol & Immunotherapy, Lublin, Poland
[4] Wroclaw Med Univ, Dept & Clin Haematol Blood Neoplasms & Bone Marro, Wroclaw, Poland
关键词
CD8(+) T-CELLS; B-LYMPHOCYTE; INFECTIOUS COMPLICATIONS; MEDIATES INHIBITION; CYCLE REGULATORS; CD152; CTLA-4; ATTENUATOR; RECEPTOR; CANCER; PROLIFERATION;
D O I
10.1155/2020/6545921
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Chronic lymphocytic leukemia (CLL) is characterized by the peripheral accumulation of neoplastic B cells and is frequently complicated by the systemic immunosuppression associated with an impairment in B and T lymphocyte activation. We hypothesized that the expression of immune checkpoint suppressors B and T lymphocyte attenuator (BTLA) and cytotoxic T lymphocyte antigen (CTLA-4) is disturbed in both lymphocyte subpopulations in CLL. The expression of CTLA-4 and BTLA mRNA was determined by real-time PCR, while CTLA-4 protein expression (surface or intracellular) was estimated in BTLA+ lymphocytes by flow cytometry. In CLL patients, we observed a higher gene transcript level of BTLA and CTLA-4 than in healthy individuals in both freshly isolated and PMA stimulated B and T cells. Remarkably, lower amounts of both inhibitory proteins were found in peripheral blood (PB) CLL B cells, whereas normal BTLA and elevated CTLA-4 were found in T cells. Consistently, there was a prevalence of CTLA-4+ cells within circulating BTLA+ T cells cells of patients confronting PB healthy cells. After in vitro stimulation, the only change found in CLL patients was a decrease in BTLA expression in B and T lymphocytes. In contrast, healthy lymphocytes responded more vigorously as regards the BTLA and CTLA expression with substantially higher frequency of CD69+ cells under the stimulating condition compared to corresponding cells from the CLL group. Our results indicate that CLL development is associated with the affected expression of BTLA and CTLA-4 checkpoint receptors in PB and its impaired expression might be associated with lowering of the threshold for B cell activation and proliferation, while upregulated CTLA-4 expression in CLL peripheral BTLA+ T cells may contribute to suppressed T cell effector functions. This hypothesis needs to be validated in future studies, which would allow us to explain how the increased or decreased expression of these molecules affects the cell function.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Expression of Immune Checkpoint Regulator CTLA-4 in Uterine Cervical Cancers
    Kassardjian, Ari
    Moatamed, Neda
    MODERN PATHOLOGY, 2019, 32
  • [2] Expression of Immune Checkpoint Regulator CTLA-4 in Uterine Cervical Cancers
    Kassardjian, Ari
    Moatamed, Neda
    LABORATORY INVESTIGATION, 2019, 99
  • [3] B Cell Subsets and Immune Checkpoint Expression in Patients with Chronic Lymphocytic Leukemia
    Ntsethe, Aviwe
    Mkhwanazi, Zekhethelo Alondwe
    Dludla, Phiwayinkosi Vusi
    Nkambule, Bongani Brian
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (03) : 1731 - 1740
  • [4] Expression of immune checkpoint molecules and activation markers in T cells from chronic lymphocytic leukemia (CL) patients
    Palma, M.
    Gentilcore, G.
    Mozaffari, F.
    Heimersson, K.
    Nasman-Glaser, B.
    Hansson, L.
    Osterborg, A.
    Mellstedt, H.
    EUROPEAN JOURNAL OF CANCER, 2016, 55 : S7 - S7
  • [5] Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia
    Karabon, Lidia
    Partyka, Anna
    Jasek, Monika
    Lech-Maranda, Ewa
    Grzybowska-Izydorczyk, Olga
    Bojarska-Junak, Agnieszka
    Pawlak-Adamska, Edyta
    Tomkiewicz, Anna
    Robak, Tadeusz
    Rolinski, Jacek
    Frydecka, Irena
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2016, 64 : S137 - S145
  • [6] Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia
    Lidia Karabon
    Anna Partyka
    Monika Jasek
    Ewa Lech-Maranda
    Olga Grzybowska-Izydorczyk
    Agnieszka Bojarska-Junak
    Edyta Pawlak-Adamska
    Anna Tomkiewicz
    Tadeusz Robak
    Jacek Rolinski
    Irena Frydecka
    Archivum Immunologiae et Therapiae Experimentalis, 2016, 64 : 137 - 145
  • [7] CTLA-4: As an Immunosuppressive Immune Checkpoint in Breast Cancer
    Dehbokri, Shaho Ghahremani
    Alizadeh, Nazila
    Isazadeh, Alireza
    Baghbanzadeh, Amir
    Abbaspour-Ravasjani, Soheil
    Hajiasgharzadeh, Khalil
    Baradaran, Behzad
    CURRENT MOLECULAR MEDICINE, 2023, 23 (06) : 521 - 526
  • [8] Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody
    Ciszak, Lidia
    Frydecka, Irena
    Wolowiec, Dariusz
    Szteblich, Aleksandra
    Kosmaczewska, Agata
    TUMOR BIOLOGY, 2016, 37 (03) : 4143 - 4157
  • [9] The Immune Checkpoint BTLA Expression: A Potential Prognostic Biomarker for Acute Myeloid Leukemia Patients
    Radwan, Sara
    Elleboudy, Nooran
    Nabih, Nermeen
    El-kholy, Amal
    Kamal, Amany
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S198 - S198
  • [10] Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia
    Motta, M
    Rassenti, L
    Shelvin, BJ
    Lerner, S
    Kipps, TJ
    Keating, MJ
    Wierda, WG
    LEUKEMIA, 2005, 19 (10) : 1788 - 1793